Abstract 1641P
Background
Sarcomas are a group of soft-tissue and bone malignancies of mesenchymal origin comprising more than 80 entities. Universally perceived as rare malignancies, the appropriate management of sarcomas involves a plethora of challenges that begin with accurate epidemiological data, vital in establishing health policies and strategies to improve care. However, the burden of this group of diseases is largely unknown in many countries. We sought to estimate the epidemiological landscape of soft-tissue (STS) and bone sarcomas (BS) in Brazil using an integrated data-capture algorithm.
Methods
A comprehensive dataset was built using publicly available data from the DataSUS National Chemotherapy database, Cancer Hospital Registry database, National Health Agency Beneficiaries database and the Brazilian Institute of Geography and Statistics (IBGE) population census estimates. Outcomes for BS and STS extracted from the dataset included incidence, prevalence, staging and overall survival (OS). OS was calculated with Kaplan Meier technique, prevalence/incidence calculations were based on linear regression.
Results
Records from 7529 sarcoma patients (pts), 4350 with STS and 3179 with BS, inputted between 2007 and 2017, were included. There were 3889 males (51.7%) and 3638 females (48.3%), and the median age at diagnosis was 41 years. 91% of the pts were treated in the public health system and 9% in supplementary private health care. The crude incidence of sarcomas ranged from 4912 to 8090 new cases/year, with an ascending tendency over time, resulting in incidence rates of 2.50 to 3.84 new cases/100.000 inhabitants/year. Median OS for pts with metastatic STS and BS were 12.4 and 17.3 months, respectively. For all staging groups, BS pts had superior OS when compared to STS pts. In both STS and BS cohorts, pts treated in the public health system had inferior OS (p<0.0001).
Conclusions
This is the first study to provide evidence regarding the epidemiology of sarcomas in Brazil. The discrepancies in outcomes of pts treated in the public and private setting are alarming. The use of this comprehensive data-capture algorithm allowed for the development of a robust database and estimates with a high level of accuracy and statistical value.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Roche.
Disclosure
R. Ramella Munhoz: Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi; Honoraria (self), Speaker Bureau/Expert testimony: Merck-Serono. R. Schmerling: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck-Serono; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche ; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Sanofi; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Research grant/Funding (institution): Array. R. Rol, C.B. de Lima: Full/Part-time employment: F. Hoffmann–La Roche AG.